2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-183344
    IL-1β-IN-4 3056856-56-2
    IL-1β-IN-4 is a selective IL-1β competitive binder. IL-1β-IN-4 interferes with the interaction between IL-1β and its cognate receptor IL-1R1, with an IC50 of 8.3 μM. IL-1β-IN-4 can be used in studies related to inflammatory and immune diseases.
    IL-1β-IN-4
  • HY-183357
    GABAAR/5-HT2AR modulator-1 98%
    GABAAR/5-HT2AR modulator-1 is an orally active and brain-penetrant GABAAR agonist and 5-HT2AR antagonist with Kd values of 0.89 and 0.78 μM. GABAAR/5-HT2AR modulator-1 blocks 5-HT-stimulated IP1 accumulation, inducing a chloride current, reduces LPS (HY-D1056)-induced increases of ROS, NO, TNF-α, IL-6, IL-1β, iNOS, and COX-2 levels. Antidepressant agent 11 dihydrochloride inhibits NF-κB pathway activation by reducing IκBα and p65 phosphorylation and blocking p65 nuclear translocation. GABAAR/5-HT2AR modulator-1 alleviates depression-like behaviors in LPS-challenged and chronic restraint stress-challenged mice, and protects hippocampal neurons against inflammation-mediated damage.
    GABAAR/5-HT2AR modulator-1
  • HY-183366
    HDAC1-IN-14
    HDAC1-IN-14 is an indole-based benzamide selective HDAC1 inhibitor with an IC50 of 77 nM. HDAC1-IN-14 acts as an antiproliferative agent, with GI50 values ranging from nanomolar to low micromolar levels in various cancer cells. HDAC1-IN-14 induces G0-G1 cell cycle arrest in colon cancer cells. HDAC1-IN-14 upregulates the expression of Caspase-3, Cyto-C and Bax, and downregulates the expression of AKT-1. HDAC1-IN-14 can be used in research related to leukemia, non-small cell lung cancer, colon cancer, central nervous system cancer, melanoma, ovarian cancer, renal cancer, prostate cancer and breast cancer.
    HDAC1-IN-14
  • HY-183367
    Anti-inflammatory agent 115 1504587-21-6 98%
    Anti-inflammatory agent 115 is a potent anti-inflammatory agent. Anti-inflammatory agent 115 reduces secretion of myeloperoxidase (MPO), TNF-α, IL-1β, and IL-6. Anti-inflammatory agent 115 decreases ear tissue thickness and neutrophil infiltration in 12-O-tetradecanoylphorbol-13-acetate (TPA) (HY-18739)-induced topical edema in mice. Anti-inflammatory agent 115 can be used for the research of inflammatory diseases.
    Anti-inflammatory agent 115
  • HY-183370
    JAK2/STAT3-IN-2
    JAK2/STAT3-IN-2 is an orally active JAK2/STAT3 inhibitor. JAK2/STAT3-IN-2 inhibits the phosphorylation of tyrosine residues in JAK2 and STAT3, blocks downstream signal transduction, disrupts the dimerization and nuclear translocation of STAT3, and suppresses pro-inflammatory transcriptional activity. JAK2/STAT3-IN-2 inhibits the expression of IL-17A and IL-17F, reduces immune cell infiltration, and inhibits the production of NO simultaneously. JAK2/STAT3-IN-2 exerts a protective effect in a mouse model of ulcerative colitis induced by DSS (HY-116282C). JAK2/STAT3-IN-2 can be used for the research of ulcerative colitis.
    JAK2/STAT3-IN-2
  • HY-18342R
    Diflunisal (Standard) 22494-42-4 98%
    Diflunisal (Standard) is the analytical standard of Diflunisal. This product is intended for research and analytical applications. Diflunisal (MK-647) is a salicylate derivative with nonsteroidal anti-inflammatory and uricosuric properties, which is used alone as an analgesic and in rheumatoid arthritis patients. The mechanism of action of diflunisal is as a Cyclooxygenase (COX) Inhibitor.
    Diflunisal (Standard)
  • HY-183440
    Amine-C2-piperazine-C4-OH 1249297-44-6 98%
    Amine-C2-piperazine-C4-OH is a flexible alkyl linker component that can be used in the synthesis of PROTAC ALK5 Degrader-1 (HY-183785). Amine-C2-piperazine-C4-OH can be applied to the research of pulmonary fibrosis.
    Amine-C2-piperazine-C4-OH
  • HY-183441
    ALK5 ligand-1 3125240-66-3 98%
    ALK5 ligand-1 (a31's ALK5 ligand) is a ligand of Anaplastic lymphoma kinase ALK5 with higher selectivity for ALK5 than for ALK4. ALK5 ligand-1 can be used to synthesize PROTAC degraders targeting ALK5. ALK5 PROTACs induce ALK5 degradation dependent on the ubiquitin-proteasome system and exert antifibrotic activity. ALK5 ligand-1 can be used in studies of pulmonary fibrosis.
    ALK5 ligand-1
  • HY-183442
    ALK5 ligand-1-amine-C2-piperazine-C4-OH 98%
    ALK5 ligand-1-amine-C2-piperazine-C4-OH is a conjugate of a ligand targeting ALK5 and a PROTAC linker. ALK5 ligand-1-amine-C2-piperazine-C4-OH can be used to synthesize the PROTAC degrader (a31). ALK5 PROTACs induce UPS-dependent and selective degradation of ALK5 over ALK4. ALK5 ligand-1-amine-C2-piperazine-C4-OH can be applied to research on pulmonary fibrosis.
    ALK5 ligand-1-amine-C2-piperazine-C4-OH
  • HY-183537
    KSI-028
    KSI-028 is a STING inhibitor. KSI-028 disrupts STING-mediated signal transduction, reduces IFN-β and pro-inflammatory cytokine (IL-6, IL-1β and TNF-α) production. KSI-028 inhibits the phosphorylation of STING, TBK1, IRF3, and STAT1. KSI-028 attenuates renal and hepatic injury in a Cisplatin (HY-17394)-induced acute kidney injury mouse model.
    KSI-028
  • HY-183545
    sEH-IN-24 3121405-85-1 98%
    sEH-IN-24 is an orally active soluble epoxide hydrolase (sEH) inhibitor with an IC50 of 1.9 nM. sEH-IN-24 inhibits the pro-inflammatory cytokines TNF-α and IL-6. sEH-IN-24 exhibits anti-inflammatory effects and exerts analgesic activity in vivo. sEH-IN-24 prevents pancreatic edema, inflammation and parenchymal atrophy. sEH-IN-24 can be used for the research of acute pancreatitis.
    sEH-IN-24
  • HY-183548
    XW-17 98%
    XW-17 is a PARP14 inhibitor with an IC50 of 3.03 nM and selectivity over other PARP family members.XW-17 suppresses PARP14-mediated mono-ADP-ribosylation, engages and stabilizes endogenous PARP14 protein.XW-17 attenuates skin lesions and decreases expression of IL-4, IL-13, IgE, and IL-17A in an atopic dermatitis-like mouse model.XW-17 can be used for the research of atopic dermatitis.
    XW-17
  • HY-183564
    RIPK1/RIPK3-PPI-IN-1 2915280-95-2 98%
    RIPK1/RIPK3-PPI-IN-1 is an orally active dual-target inhibitor of RIPK1/RIPK3, with a Kd value of 2.4 nM for RIPK1 and 24 nM for RIPK3. RIPK1/RIPK3-PPI-IN-1 inhibits the phosphorylation of RIPK1, RIPK3 and MLKL, thereby suppressing necroptosis. RIPK1/RIPK3-PPI-IN-1 restores body temperature, improves survival rate, and reduces IL-1β/IL-6 levels in serum and multiple organs of Mus musculus, thus alleviating TNF-α-induced systemic inflammatory response syndrome. RIPK1/RIPK3-PPI-IN-1 can be used in research related to systemic inflammatory response syndrome.
    RIPK1/RIPK3-PPI-IN-1
  • HY-183573
    PTPRO-IN-1
    PTPRO-IN-1 is a selective, orally active PTPRO inhibitor with an IC50 of 0.16 μM. PTPRO-IN-1 exhibits IC50 values of 2.4 μM, 2.33 μM and 2.13 μM against PTPN22, PTP1B and PTPRT, respectively, and shows almost no inhibitory activity against STEP/SSH2. PTPRO-IN-1 inhibits the TLR4/NF-κB signaling pathway in macrophages, ameliorates colonic pathological conditions and suppresses the secretion of pro-inflammatory cytokines by T cells. PTPRO-IN-1 can be used for the research of inflammatory bowel disease.
    PTPRO-IN-1
  • HY-183578
    TYY-31
    TYY-31 is an orally active, selective S1PR1 agonist with an EC50 of 1.13 pM. TYY-31 promotes the phosphorylation of ERK1/2. TYY-31 exerts anti-inflammatory and immunosuppressive effects, ameliorates DSS-induced colitis in mice, and reduces peripheral blood lymphocyte counts in mice in a dose-dependent manner. TYY-31 can be used for the research of ulcerative colitis.
    TYY-31
  • HY-183647
    iNOs-IN-9 98%
    iNOs-IN-9 is a selective inducible nitric oxide synthase (iNOS) inhibitor with an IC50 of 82 nM against hiNOS. iNOs-IN-9 reduces cytokine-induced inflammatory responses and cell necrosis in inflammatory cell models. iNOs-IN-9 can be used for research related to psoriasis.
    iNOs-IN-9
  • HY-183651
    15-PGDH-IN-5 1714984-32-3 98%
    15-PGDH-IN-5 (compound 5) is a sulfoxide-derived 15-PGDH inhibitor. 15-PGDH-IN-5 exhibits higher metabolic stability and superior in vivo exposure compared with the lead compound SW033291 (HY-16968). 15-PGDH-IN-5 inhibits the irreversible oxidative catabolism of PGE2 by 15-PGDH, thereby enhancing the tissue-specific bioavailability of endogenous PGE2. 15-PGDH-IN-5 exerts anti-inflammatory effects and accelerates tissue repair and regeneration, and it is used in studies on tissue injury and fibrosis-related diseases such as inflammatory bowel disease and idiopathic pulmonary fibrosis.
    15-PGDH-IN-5
  • HY-183658
    URAT1/GLUT9-IN-3 98%
    URAT1/GLUT9-IN-3 is an orally active URAT1/GLUT9 dual inhibitor with IC50 values of 4.01 and 1.60 μM. URAT1/GLUT9-IN-3 inhibits URAT1-mediated uric acid uptake and GLUT9-mediated uric acid transport, reducing renal urate reabsorption. URAT1/GLUT9-IN-3 reduces serum uric acid levels in hyperuricemic mice. URAT1/GLUT9-IN-3 can be used for the researches of gout and hyperuricemia.
    URAT1/GLUT9-IN-3
  • HY-183671
    NSC850143 98%
    NSC850143 is an antiproliferative agent. NSC850143 induces antiproliferative and cytotoxic effects in aggressive tumor cells. NSC850143 can be used in the research of cancers such as leukemia, non-small cell lung cancer, colon cancer, central nervous system cancer, melanoma, ovarian cancer, renal cancer, prostate cancer and breast cancer.
    NSC850143
  • HY-183673
    COX-1/2-IN-12 3068797-68-9 98%
    COX-1/2-IN-12 is an orally active dual inhibitor of COX-1 and COX-2, with an IC50 of 41.6 nM against human COX-1 and an IC50 of 31.1 nM against human COX-2. COX-1/2-IN-12 induces antinociceptive activity and inhibits edema in in vivo experiments. COX-1/2-IN-12 can be used in research related to inflammation and pain.
    COX-1/2-IN-12
Cat. No. Product Name / Synonyms Application Reactivity